<DOC>
	<DOCNO>NCT02126579</DOCNO>
	<brief_summary>The purpose study learn effect ( good bad ) experimental vaccine ( LPV7 ) plus tetanus peptide substance call polyICLC , resiquimod , Montanide ISA-51 melanoma . We also look whether experimental vaccine drug cause change immune system .</brief_summary>
	<brief_title>Phase I/II Trial Long Peptide Vaccine ( LPV7 ) Plus TLR Agonists</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Poly ICLC</mesh_term>
	<criteria>Histologically cytologically proven Stage IIB IV melanoma render clinically free disease surgery , therapy , spontaneous remission within 6 month prior registration . Patients may melanoma cutaneous , mucosal unknown primary site Patients small radiologic clinical finding may eligible Patients treated brain metastasis may eligible follow true : Total number brain metastasis ever less equal 3 The brain metastases completely remove surgery treat completely stereotactic radiotherapy There evident growth brain metastasis since treatment No treat brain metastasis great 2 cm time protocol entry Patients must least 1 intact axillary and/or inguinal lymph node basin ECOG performance status 01 Lab parameter follow : HLAA1 , A2 , A3 , B35 , B51 ANC &gt; 1000/mm3 Platelets &gt; 100,000/mm3 Hemoglobin &gt; 9 g/dL AST ALT 2.5 x ULN Bilirubin 2.5 x ULN Alkaline Phosphatase 2.5 x ULN Creatinine 1.5 x ULN HGBA1C level &lt; 7 % Patients melanoma uveal ocular primary site Patients currently receive systemic therapy within 4 week study registration . Gamma knife stereotactic radiosurgery must administer within 1 week prior study registration . Patients currently receive nitrosoureas within precede 6 week . Patients receive CTLA4 , PD1 , PDL1 , CD137 , CD27 within prior 12 month . Patients know suspected allergy component vaccine HIV positive active Hepatitis C virus Patients receive follow medication within 4 week exclude : Agents immunomodulating activity ( exception nonsteroidal antiinflammatory agent topical steroid ) Allergy desensitization injection Systemic corticosteroid , administer parenterally orally . Inhaled steroid ( e.g . Advair , Flovent , Azmacort ) permit . Topical corticosteroid acceptable include steroid low solubility administer nasally local effect ( e.g . Nasonex ) Any growth factor ( e.g . GMCSF , GCSF , erythropoietin ) . Interferon therapy Interleukin2 interleukins Other investigational drug investigational therapy currently receive receive within 1 month Pregnancy possibility become pregnant study . And woman breastfeed . Must prior autoimmune disorder require cytotoxic immunosuppressive therapy , autoimmune disorder visceral involvement . The following exclusionary : Presence laboratory evidence autoimmune disease ( e.g . positive ANA titer ) without symptom Clinical evidence vitiligo Other form depigmenting illness Mild arthritis require NSAID medication Patients medical contradiction potential problem comply protocol , opinion investigator Patients Class III IV heart disease ( accord NYHA classification ) Patients body weight &lt; 110 lb .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>melanoma</keyword>
	<keyword>neoplasm</keyword>
	<keyword>Poly ICLC</keyword>
	<keyword>Freund 's Adjuvant</keyword>
	<keyword>Metastatic melanoma</keyword>
	<keyword>resiquimod</keyword>
	<keyword>adjuvant</keyword>
	<keyword>peptide vaccine</keyword>
</DOC>